FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): August 25, 2003

 

PRO-PHARMACEUTICALS, INC.


(Exact Name of Registrant as Specified in its Charter)

 

Nevada


(State or Other Jurisdiction of Incorporation)

 

    000-32877    04-3562325     
   
  
  
    (Commission File Number)    (IRS Employer Identification No.)     
    189 Wells Avenue, Newton, Massachusetts    02459     
   
  
  
    (Address of Principal Executive Offices)    (Zip Code)     

 

(617) 559-0033


(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable


(Former Name or Former Address, If Changed Since Last Report)

 



Item 5.    Other Events and Regulation FD Disclosure

 

Our Quarterly Report on Form 10-QSB filed on August 14, 2003 for the quarter ended June 30, 2003 reported that Ms. Sheila Jayaraj, a former employee, filed a complainant letter against us with the Occupational Safety and Health Administration (OSHA) of the U.S. Department of Labor. Please see our Quarterly Report for additional detail.

 

Since the filing of our Quarterly Report:

 

1. By letter dated August 25, 2003, the Department of Labor reported to Ms. Jayaraj’s counsel that “Following an investigation of this matter by a duly authorized investigator, the Secretary of Labor,” acting through the Regional Administrator for OSHA, “finds that there is no merit to the allegations that [Pro-Pharmaceuticals] violated Complainant’s rights under [applicable federal law].” The letter later stated that the complaint is dismissed.

 

2. Ms. Jayaraj in a letter dated September 24, 2003 objected to the Secretary’s findings and requested a hearing on the record by an Administrative Law Judge at the Department of Labor.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PRO-PHARMACEUTICALS, INC

By:

 

/s/    DAVID PLATT


   

David Platt

Chief Executive Officer

Date: September 26, 2003

 

2